![1]()
News
Treatment of heart failure with preserved ejection fraction is a work in progress
January 13, 2020
Although the disorder has a lower mortality than heart failure with reduced ejection fraction, it places a significant burden on health care systems.
![1]()
News
Farxiga granted Priority Review for treatment of adults with HFrEF
January 6, 2020
The Food and Drug Administration is reviewing dapagliflozin for reducing the risk of cardiovascular death or worsening of heart failure in adults with heart failure with reduced ejection fraction based on DAPA-HF.
![1]()
News
ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding
December 16, 2019
LOS ANGELES – Use of novel oral anticoagulants may be preferred over vitamin K antagonists in patients with diabetes and AFib.
![1]()
News
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
November 25, 2019
PHILADELPHIA – The SGLT2 inhibitor had similar efficacy in the elderly, and across the spectrum of baseline symptom status.
![1]()
News
Findings confirm link between methimazole and risk for acute pancreatitis
November 21, 2019
CHICAGO – However, there is no evidence of a cumulative dose effect.
![1]()
News
Glycemic Control eQUIPS yields success at Dignity Health Sequoia Hospital
November 11, 2019
The tools available in the GC eQUIPS program are powerful for data analysis and benchmarking.
News
New model for CKD risk draws on clinical, demographic factors
November 8, 2019
The equation has demonstrated high discrimination and variable calibration across a range of populations.
News
Dapagliflozin approved for reducing HF hospitalization in diabetes
October 21, 2019
It is the first SGLT2 inhibitor approved in the United States for this indication in adults with type 2 disease.
![1]()
News
Certain diabetes drugs may thwart dementia
October 21, 2019
COPENHAGEN – Intriguing findings from a Danish national registry study.
![1]()
News
FDA adds diabetic kidney disease, heart failure indications to canagliflozin
September 30, 2019
This marks the first time in 20 years that a drug has been indicated for diabetic kidney disease treatment, according to the manufacturer.
